The human whipworm, which infects 500 million people and can damage physical and mental growth, is killed at egg and adult stage by a new drug class developed at the Universities of Manchester and Oxford and University College London.
Current treatments for human whipworm are based on 1960s drugs initially developed for livestock and have a low success rate in people. There are also no vaccines available.
As a result there’s a desperate need for new treatments. The team from the three UK universities, whose results have been published in the journal PLOS Neglected Tropical Diseases, studied a class of dihydrobenzoxazepinones, not previously associated with controlling whipworms.
The researchers found that the compounds kill the adult stages of the whipworm much more effectively than existing drugs.
Parasite immunologist, Professor Kathryn Else from The University of Manchester said: “Eradicating the whipworm requires more effective drugs, improving hygiene and vaccine development. The compounds we have discovered could address the first two of these.”
"Although we rarely see whipworm infection in the UK, it is a serious and damaging problem in many parts of the world and if we can develop this treatment, the lives of many people could be improved"
Professor Kathryn Else
Whipworm eggs are also affected by the compounds. Whipworm eggs are passed from infected faeces into people by hand to mouth contact. This often happens in unsanitary toilets or areas where people live close together. The eggs are highly resistant to extreme temperature changes and ultraviolet radiation and can remain viable in the environment for many years.
However the new compounds are effective against the eggs and could be developed into a spray which can stop infection at source.
The researchers are now modifying their compounds to make them effective enough for a treatment in humans, and one that can be turned into a product used in the developing countries most affected.
Professor Else said: “This team brought expertise from immunology, medicinal chemistry and neurobiology and really shows how combining across disciplines and institutions can lead to important new discoveries.
“Although we rarely see whipworm infection in the UK, it is a serious and damaging problem in many parts of the world and if we can develop this treatment, the lives of many people could be improved.”
This article has been republished from materials provided by The University of Manchester. Note: material may have been edited for length and content. For further information, please contact the cited source.
Partridge, F.A., Murphy, E.A., Willis, N.J., Bataille, C.J.R., Forman, R., Heyer-Chauhan, N., Marinič, B., Sowood, D.J.C., Wynne, G.M., Else, K.J., Russell, A.J. and Sattelle, D.B. (2017) ‘Dihydrobenz[e][1, 4]oxazepin-2(3H)-ones, a new anthelmintic chemotype immobilising whipworm and reducing infectivity in vivo’, PLOS Neglected Tropical Diseases, 11(2), p. e0005359. doi: 10.1371/journal.pntd.0005359.
Researchers Democratize Neuroscience by Making it Easier to Share Brain Imaging DataNews
Researchers have developed a set of tools to make one critical area of big data research — that of our central nervous system — easier to share.READ MORE
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE